Page last checked 2026-09-07

Research compound · not FDA-approved

CJC-1295

Also written CJC 1295 or CJC1295.

CJC-1295 is a redesigned copy of the hormone that tells your pituitary to release growth hormone. One version bonds to a protein in your blood, which stretches its life from minutes into days.

What matters first

Why people look it up: It is sold for the same wishlist as ipamorelin, and usually stacked with it: muscle, fat loss, recovery and sleep.
What the evidence shows: The human studies measured one thing, and it was growth hormone in the blood. None of them reported muscle, fat, strength or anything a person would notice. Most material sold under the name is the short-acting molecule, which was never in those studies.
Dose status: CJC-1295 is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about CJC-1295

CJC-1295 properly names a modified fragment of growth hormone-releasing hormone. The version studied in people carries a reactive chemical arm, the drug-affinity complex, which bonds the peptide to albumin in the blood. That stretches its life from minutes into days. Most material sold under the name has no such arm, so it is a different molecule: modified GRF 1-29, which clears fast. Phase 1 work showed the long-acting version raises growth hormone, but no trial showed what that achieves.

CJC-1295 research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
Topic	Value
Strongest source	limited human data
FDA approval	Not FDA-approved
Studied dosing	30–60 mcg per kilogram of body weight — the two of four rising single-dose levels the authors singled out as safe and relatively easy for healthy adults aged 21 to 61 to handle, using the version carrying the drug-affinity complex; a single injection raised growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for nine to eleven days — from clinical trials
Studied dosing	60–90 mcg per kilogram of body weight, as a single injection, with growth hormone sampled overnight a week later in healthy men aged 20 to 40; the two doses did not differ from each other in effect — from clinical trials
What people report using	1–2 mg a week, split over one or two injections of the drug-affinity-complex version; this is reported practice, distinct from the weight-based single and repeated doses in the cited human studies — no trial has tested this quantity
Typical vials	5 mg

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

The row headed “what people report using” is not evidence. No trial produced that quantity. It is printed because it is what circulates, and because it is better read here, beside what the studies actually did, than on a page that is selling the vial. It describes a practice. It is not a starting point.

What the evidence for CJC-1295 is

People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.

limited human data

What it establishes: It shows that people have received it and that some human information exists.
What it does not establish: It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.

Evidence snapshot and shareable image

Evidence snapshot

Foreign approval or limited human data

The fastest way to see what kind of evidence this page is built on.

Regulation: Not FDA-approvedNo US prescribing label
Dose source: Human study2 reported dose rows
Safety evidence: 5 listed safety findingsCommon and serious effects shown apart
Sources: 4 cited sourcesMedical review complete · 2026-09-07

Open the shareable evidence image

CJC-1295 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Where CJC-1295 is in clinical trials

1 registered study; the program has reached phase 2. Nothing is currently open or enrolling.

Phase 2Stopped early
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
ConjuChem · Obesity, HIV Infections · 120 participants planned · started December 2005
NCT00267527 on ClinicalTrials.gov

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-27

Every compound we track, and what stage each one has reached →

Regulatory status

One product name covers two substances here, and the difference is not cosmetic.

With the affinity complex the peptide lasts days; without it, minutes. So a protocol, a quantity or a risk written for one does not describe the other. Buyers routinely cannot tell which they hold.

The company that created the long-acting form dropped it, leaving no sponsor, no investigational filing and no pharmacopeial standard for either version.

Full regulatory tracker →

How CJC-1295 compares

Each page says which kind of comparison it is: one trial that tested both, or two separate trials read side by side — which is much weaker, however close the numbers look.

Where CJC-1295 stands in tesamorelin vs cjc-1295

Dosing, source strength, half-life and reactions for tesamorelin vs cjc-1295, cited row by row past CJC-1295.

Where to go next on CJC-1295

The related pages keep each topic with its evidence.

Why CJC-1295 carries no boxed warning

7 standing caveats on the CJC-1295 page, written out rather than implied.

CJC-1295 dosing evidence, without an approved schedule

3 published CJC-1295 dose values, each linked to the original source.

CJC-1295 concentration in the CJC-1295 reconstitution calculator

The concentration in mg/mL for every CJC-1295 vial and water pairing, printed in full.

Mixing a 5 mg CJC-1295 vial, water volume by water volume

What each bacteriostatic-water volume does to a 5 mg CJC-1295 vial, in mg/mL and units.

Where Australia Peptide products access differs from CJC-1295

CJC-1295 beside it — state and territory possession controls are not rewritten as one national rule.

The stack page CJC-1295 belongs to

5 traps specific to this pair, written out past CJC-1295.

Where Canada Peptide products access differs from CJC-1295

CJC-1295 beside it — a 90-day quantity limit is a boundary inside eligible cases, not a general import permission.

Where CJC-1295 sits among the weight loss compounds

15 compounds people take for weight loss, and what each was measured against, with CJC-1295 as one example

Who else is sold for muscle growth besides CJC-1295

What people take it for and what the muscle growth page shows stay in separate columns, including CJC-1295

Who else is sold for sleep besides CJC-1295

What people take it for and what the sleep page shows stay in separate columns, including CJC-1295

Safety notes

Two different molecules are sold under this one name. One lasts minutes, the other days
Vial strength is the same for both versions, so it cannot tell them apart
Both published human studies used the drug-affinity-complex version. The shorter-acting modified GRF 1-29 is sold under the same name. It has no human dosing study behind it
Every published quantity is per kilogram of body weight. No vial arithmetic follows from it without a weight
Early human work showed a growth-hormone rise over days, but it measured hormone levels only. No trial has reported a body-composition, strength or clinical outcome
A steady rise in growth hormone is a different state. The body normally makes pulses instead
The World Anti-Doping Agency bans growth-hormone releasing factors at all times. That covers in and out of competition

Questions about CJC-1295

Is CJC-1295 FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is CJC-1295 taken?

By injection under the skin, per kilogram of body weight. The dosing page has every step, with the source on each row.

How does CJC-1295 differ from the other compounds in this class?

CJC-1295 has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.

What is not known about CJC-1295?

It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Is there a CJC-1295 dosing schedule on this site?

Not a schedule — there is no approved schedule to publish here. What you get instead is the trial dosing program: the doses each arm received and how the protocol worked up to them. The studied range was 30–60 mcg per kilogram of body weight — the two of four rising single-dose levels the authors singled out as safe and relatively easy for healthy adults aged 21 to 61 to handle, using the version carrying the drug-affinity complex; a single injection raised growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for nine to eleven days. See what the trials tested.

Questions readers ask

What exactly does CJC-1295 do?

In the two published human studies it raised growth hormone and IGF-I, and held them up for days. A single injection lifted growth hormone two- to tenfold for six days or more. IGF-I stayed one-and-a-half to threefold above baseline for nine to eleven days.

What that achieves went untested. Both studies sampled blood and stopped there. No trial has reported a change in body shape, strength, or anything a person would notice.

Does CJC-1295 suppress testosterone?

Nobody has measured testosterone on it. The two human trials tracked growth hormone and IGF-I, and no sex hormone appeared on the list. So there is no evidence either way.

Both trials were short as well — one ran twenty-eight days, the other forty-nine, in healthy adults. Nothing has looked at what repeated use does to other hormones.

What are the downsides of CJC-1295?

The first is that you may not know which molecule you are holding. Two different substances are sold under this one name, and the vial strength is identical for both. The version studied in people carries a chemical arm that keeps it in the blood for days; the other clears in minutes.

The second is that no controlled trial of what it achieves was ever finished, and the company that made the long-acting form dropped it. Anti-doping rules ban growth-hormone releasing factors at all times, in and out of competition.

How many times a week should I take CJC-1295?

No published trial set a weekly pattern. Both human studies gave one injection and then watched what followed. Both quantities were set per kilogram of body weight, which is not a figure that converts without a weight.

What circulates is one to two milligrams a week, split across one or two injections of the long-acting version. A 2026 review prints that as a self-reported practice and says in the same table that such values are not clinically validated. Nothing has tested it.

4primary sources, each with the day we read it — open the documents used on this page